Oncolytics Biotech Inc (ONCY)

0.28
0.01 3.36
OTC : Health Care
Prev Close 0.27
Open 0.27
Day Low/High 0.27 / 0.29
52 Wk Low/High 0.24 / 1.40
Volume 69.43K
Avg Volume 361.10K
Exchange OTC
Shares Outstanding 117.98M
Market Cap 34.19M
EPS -0.18
Div & Yield N.A. (N.A)

Latest News

Interesting ONCY Call Options For May 17th

Interesting ONCY Call Options For May 17th

Investors in Oncolytics Biotech Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCY options chain for the new May 17th contracts and identified the following call contract of particular interest.

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

2 Health Care Stocks Under $10 to Trade for Breakouts

2 Health Care Stocks Under $10 to Trade for Breakouts

Keep these health care stocks on your radar.

3 Biotech Stocks Under $10 to Trade for Breakouts

3 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers

Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers

Advanced Micro and Alaska Communications lead nine stocks trading under $5 as speculative stocking stuffers for possible positive returns in 2014.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation Of ONCOLYTICS BIOTECH INC. For Possible Violations Of Federal Securities Laws

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation Of ONCOLYTICS BIOTECH INC. For Possible Violations Of Federal Securities Laws

Levi & Korsinsky is investigating Oncolytics Biotech Inc. (“Oncolytics” or the “Company”) (NasdaqCM: ONCY) for possible violations of federal securities laws.

Oncolytics Biotech Shades Truth On Failed Cancer Study

Oncolytics Biotech Shades Truth On Failed Cancer Study

There are too many red flags to count in the way Oncolytics Biotech spins results from the Reolysin head and neck cancer study.

Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13

Biotech Stock Mailbag: Ariad, NewLink, Zogenix, 5 Falling Stocks For Rest of '13

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Oncolytics Pumps Stock With Worsening Lung Cancer Drug Data

Oncolytics Pumps Stock With Worsening Lung Cancer Drug Data

Oncolytics claims positive Reolysin results, fails to mention falling response rates.

Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech

Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta

Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Why Expect More Price Swings From These 4 Biotechs

Why Expect More Price Swings From These 4 Biotechs

Crish Lau, Kapitall Contributor  Companies in the biotechnology space are often trade like speculative investments. Speculation for FDA approvals may [...]

Stocks Finish Higher Ahead of Fed Decision

Stocks Finish Higher Ahead of Fed Decision

The major U.S. equity averages edge up ahead of the central bank's policy decision on Thursday. Apple shares enjoy a boost from the debut of the iPhone 5.

Biotech Stock Mailbag: Oncolytics, Sarepta, Delcath, Peregrine

Biotech Stock Mailbag: Oncolytics, Sarepta, Delcath, Peregrine

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

8 Stocks Under $10 Moving Higher

8 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BIO CEO Conference Live Blog

TheStreet's biotech columnist, Adam Feuerstein, will be providing live coverage from the BIO CEO biotech investor conference.

Amgen Makes Bet on Viral Skin Cancer Killer

Amgen's purchases BioVex to get into the cancer immunotherapy game.

Biotech's Brighter Corners

Speculative opportunities abound in the small- and mid-cap universe, but only for aggressive market players.

Increased Risk of News-Driven Shock Gaps

Every quarter brings a few surprises, and this one could be open to more heading into the November elections.

Columbia Laboratories, Cardionet: Early Volume Plays

Several stocks trading near $5, including Columbia Laboratories, were poised to move on above-average volume Tuesday.

Poniard, Netlist: Early Volume Plays

Several stocks trading under $5 were poised to move on above-average volume during Wednesday's session.

Wednesday's Small-Cap Winners & Losers

The Pantry tumbles on guidance.

Wednesday's Health Winners & Losers

GlaxoSmithKline falls on disappointing quarterly results.

Monday's Health Winners & Losers

Discovery Laboratories is rising.

Tuesday's Small-Cap Winners & Losers

Globalstar falls due to concerns over deterioration of its satellites.

Health Stocks in Motion

Biogen and Elan lead the sector lower after Tysabri is pulled.

Weekend Reading: Markets Seem Frozen With Fear

Focusing on terror threats, markets have been locked in an 8% range for 128 consecutive sessions.